W L Roberts

Summary

Publications

  1. ncbi Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2
    W L Roberts
    Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
    Clin Chem 47:418-25. 2001
  2. ncbi Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications
    W L Roberts
    Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
    Clin Chem 46:461-8. 2000
  3. ncbi Effects of sickle cell trait and hemoglobin C trait on determinations of HbA1c by an immunoassay method
    W L Roberts
    Department of Pathology, University of Mississippi Medical Center, Jackson 39216, USA
    Diabetes Care 21:983-6. 1998
  4. ncbi Comparison of four commercial urinary albumin (microalbumin) methods: implications for detecting diabetic nephropathy using random urine specimens
    W L Roberts
    Department of Pathology, University of Mississippi Medical Center, Jackson 39216, USA
    Clin Chim Acta 273:21-33. 1998
  5. ncbi Performance characteristics of a point of care C-reactive protein assay
    W L Roberts
    Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
    Clin Chim Acta 314:255-9. 2001
  6. ncbi Performance characteristics of four free phenytoin immunoassays
    W L Roberts
    Department of Pathology at University of Utah Health Sciences Center, Salt Lake City, USA
    Ther Drug Monit 23:148-54. 2001

Detail Information

Publications6

  1. ncbi Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2
    W L Roberts
    Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
    Clin Chem 47:418-25. 2001
    ..This application requires higher sensitivity assays than have traditionally been available in the clinical laboratory...
  2. ncbi Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications
    W L Roberts
    Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
    Clin Chem 46:461-8. 2000
    ..This new clinical application requires quantification of CRP concentrations below those traditionally measured in the clinical laboratory...
  3. ncbi Effects of sickle cell trait and hemoglobin C trait on determinations of HbA1c by an immunoassay method
    W L Roberts
    Department of Pathology, University of Mississippi Medical Center, Jackson 39216, USA
    Diabetes Care 21:983-6. 1998
    ..The measurement of HbA1c in patients with Hb variants is one area not directly addressed by the NGSP. Therefore, we assessed the comparability of two DCCT-traceable methods in samples with Hb variants...
  4. ncbi Comparison of four commercial urinary albumin (microalbumin) methods: implications for detecting diabetic nephropathy using random urine specimens
    W L Roberts
    Department of Pathology, University of Mississippi Medical Center, Jackson 39216, USA
    Clin Chim Acta 273:21-33. 1998
    ..Calibrator cross-over experiments demonstrated that some of the positive bias of the aca method could be accounted for by calibrator differences...
  5. ncbi Performance characteristics of a point of care C-reactive protein assay
    W L Roberts
    Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
    Clin Chim Acta 314:255-9. 2001
    ..C-reactive protein (CRP) is a non-specific marker of inflammation that can be used for atherosclerotic risk assessment. This application requires increased precision at low CRP concentrations compared to traditional assays...
  6. ncbi Performance characteristics of four free phenytoin immunoassays
    W L Roberts
    Department of Pathology at University of Utah Health Sciences Center, Salt Lake City, USA
    Ther Drug Monit 23:148-54. 2001
    ....